Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China
{{output}}
Aim: To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs). ... ...
